Rosiglitazone
- Generic Name
- Rosiglitazone
- Brand Names
- Avandamet, Avandia
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O3S
- CAS Number
- 122320-73-4
- Unique Ingredient Identifier
- 05V02F2KDG
- Background
Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellula...
- Indication
Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Metabolic and Renal Effects of Rosiglitazone in Kidney Transplant
- Conditions
- First Posted Date
- 2006-03-31
- Last Posted Date
- 2007-07-03
- Target Recruit Count
- 10
- Registration Number
- NCT00309309
- Locations
- 🇮🇹
Clinical Research Center for Rare Diseases, Ranica, Bergamo, Italy
Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insulin Resistance Syndrome And/Or Type 2 Diabetes
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 556
- Registration Number
- NCT00306644
- Locations
- 🇸🇪
GSK Investigational Site, Malmö, Sweden
Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.
- Conditions
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 388
- Registration Number
- NCT00306696
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus
- Conditions
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2007-04-04
- Lead Sponsor
- Aristotle University Of Thessaloniki
- Target Recruit Count
- 100
- Registration Number
- NCT00306176
- Locations
- 🇬🇷
AHEPA University Hospital of Thessaloniki, Thessaloniki, Greece
Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia
- Conditions
- First Posted Date
- 2006-03-21
- Last Posted Date
- 2006-03-21
- Lead Sponsor
- Foundation Research, Florida
- Target Recruit Count
- 30
- Registration Number
- NCT00304993
- Locations
- 🇺🇸
Foundation Research, St. Petersburg, Florida, United States
BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-
- Conditions
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 350
- Registration Number
- NCT00297063
- Locations
GSK Investigational Site
A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone
- Conditions
- Interventions
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 565
- Registration Number
- NCT00295633
- Locations
- 🇺🇸
Sunbelt Research Group, Llc, Mobile, Alabama, United States
🇺🇸Loma Linda Va Healthcare Systems, Loma Linda, California, United States
🇺🇸Mouhaffel, Assad H., West Monroe, Louisiana, United States
Effect of Rosiglitazone
- Conditions
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 12
- Registration Number
- NCT00285142
- Locations
- 🇫🇷
Centre d'Investigation Clinique, Montpellier, France
Beta Cell Function Tests Over Time In Patients With T2dm Randomized To Metformin Or Rosiglitazone
- Conditions
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2008-10-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 29
- Registration Number
- NCT00282945
- Locations
- 🇮🇱
Pfizer Investigational Site, Jerusalem, Israel
Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide
- Conditions
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4426
- Registration Number
- NCT00279045
- Locations
- 🇬🇧
GSK Investigational Site, Wigan, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.